Heavy chain immunoglobulin sequencing of Lyme disease PBMCs. Heavy chain immunoglobulin sequencing of Lyme disease PBMCs

Lyme disease (Borrelia burgdorferi infection) is increasingly recognized as a significant source of morbidity world-wide. Here, we investigated B cell responses to Lyme disease through molecular identifier-enabled antibody heavy chain sequencing of bulk B cells from PBMCs. Single-cell immunoglobulin sequencing of paired heavy- and light-chain genes from this project will also be separately deposited. Additional information regarding patient characteristics and overlap with other data from the SLICE study is available upon request. Overall design: Total mRNA was isolated from peripheral blood mononuclear cells (PBMCs) of Lyme disease patients at four timepoints: Visit 1, Untreated acute infection; Visit 3, one month after completion of treatment; Visit 5, six months after treatment; Visit 7, two years after treatment. Total mRNA was isolated from peripheral blood mononuclear cells (PBMCs) of Healthy controls at three timepoints: Visit H2, initial visit; Visit H3, six months after initial; Visit H4, one year after initial visit. cDNA was tagged with unique molecular identifiers, amplified with primers specific for immunoglobulin constant regions, and sequenced by HiSeq 2500.